Key result
Three months of anticoagulation for deep vein thrombosis or pulmonary embolism resulted in similar rates of fatal and non-fatal recurrence compared to six months (8% vs 8%; P=0.80).
Why the study?
Does three months of anticoagulation compared to six months reduce adverse outcomes in patients with deep vein thrombosis or pulmonary embolism?
RCT (n=749)
randomised
Yes
Does three months of anticoagulation compared to six months reduce adverse outcomes in patients with deep vein thrombosis or pulmonary embolism?
Absolute Event Rate: 8% vs 8%
p-value: p=0.80
Three months of anticoagulation for DVT or PE provides similar efficacy to six months but significantly reduces the risk of major hemorrhage.
No takes yet. Share an insight, caveat, or question.
Supports three-month anticoagulation after DVT or PE to reduce major bleeding; confirms equivalent recurrence prevention versus six months.
Campbell et al. (2007) conducted an RCT in deep vein thrombosis or pulmonary embolism, or both (n=749). Three months of anticoagulation vs. Six months of anticoagulation was evaluated on Fatal and non-fatal deep vein thrombosis or pulmonary embolism during and after treatment (95% CI -3.1% to 4.7%, p=0.80). Three months of anticoagulation for deep vein thrombosis or pulmonary embolism resulted in similar rates of fatal and non-fatal recurrence compared to six months (8% vs 8%; P=0.80).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: